The Current Ratio as of November 2024 (TTM) for Relmada Therapeutics, Inc. (RLMD) is 6.89

According to Relmada Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 6.89. This represents a change of -5.48% compared to the average of 7.29 of the last 4 quarters.

Relmada Therapeutics, Inc. (RLMD) Historical Current Ratio (quarterly & annually)

How has RLMD Current Ratio performed in the past?

The mean historical Current Ratio of Relmada Therapeutics, Inc. over the last ten years is 13.53. The current 6.89 Current Ratio has changed 4.99% with respect to the historical average. Over the past ten years (40 quarters), RLMD's Current Ratio was at its highest in in the December 2019 quarter at 80.21. The Current Ratio was at its lowest in in the September 2018 quarter at 0.18.

Relmada Therapeutics, Inc. (RLMD) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Relmada Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Relmada Therapeutics, Inc. (RLMD) Average Current Ratio

How has RLMD Current Ratio performed in the past?

The current Current Ratio of Relmada Therapeutics, Inc. (RLMD) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Relmada Therapeutics, Inc. (RLMD) Current Ratio vs. Peers

How is RLMD’s Current Ratio compared to its peers?

Relmada Therapeutics, Inc.’s Current Ratio is less than Cytokinetics, Incorporated (9.28), less than DICE Therapeutics, Inc. (38.14), less than Edgewise Therapeutics, Inc. (26.35), less than Karuna Therapeutics, Inc. (19.31), less than Dyne Therapeutics, Inc. (17.02), less than Third Harmonic Bio, Inc. (42.50), less than PMV Pharmaceuticals, Inc. (13.98), greater than Enochian Biosciences, Inc. (0.08), less than Revolution Medicines, Inc. (14.24), less than Pardes Biosciences, Inc. (9.81), less than Shattuck Labs, Inc. (7.96), less than Eliem Therapeutics, Inc. (60.41), greater than Champions Oncology, Inc. (0.69), less than Century Therapeutics, Inc. (10.39), less than Fusion Pharmaceuticals Inc. (10.64), less than Bicycle Therapeutics plc (17.13), less than RAPT Therapeutics, Inc. (9.90), less than NewAmsterdam Pharma Company N.V. (10.61), less than Cyteir Therapeutics, Inc. (21.89), less than Nuvation Bio Inc. (9.57), less than Magenta Therapeutics, Inc. (14.64), less than Neoleukin Therapeutics, Inc. (15.33), less than Graphite Bio, Inc. (11.47),

Build a custom stock screener for Relmada Therapeutics, Inc. (RLMD) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Relmada Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Relmada Therapeutics, Inc. (RLMD) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Relmada Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.